Drugs / RSV ΔNS2 Δ1313 I1314L Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01893554 | Jun 2013 → Apr 2023 | respiratory syncytial virus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV ΔNS2 Δ1313 I1314L Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01893554 ↗ |
| Modality | Vaccine | “Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine” NCT01893554 ↗ |
| Route | Intranasal | “RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops” NCT01893554 ↗ |